Discovery of a potent small molecule SIRT1/2 inhibitor with anticancer effects

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Sirtuins, including SIRT1 and SIRT2, are deacetylase enzymes implicated in cancer progression.
• Targeting these enzymes presents a potential strategy for cancer therapy.

Purpose of the Study:

• To identify small molecules that inhibit SIRT1 and SIRT2 activity.
• To evaluate the anticancer potential of the identified inhibitor, toxoflavin.

Main Methods:

• In vitro deacetylase assays using purified SIRT1 and SIRT2 proteins.
• Cell viability assays (GI50) on various cancer cell lines, including A549.
• Western blot analysis to assess acetylation levels of SIRT1 and SIRT2 substrates (p53 and α-tubulin).
• Synthesis of toxoflavin derivatives to explore structure-activity relationships.

Main Results:

• Toxoflavin was identified as a potent inhibitor of SIRT1 and a less potent inhibitor of SIRT2 in vitro.
• Toxoflavin exhibited significant growth inhibition (GI50 = 48 nM) in A549 lung cancer cells.
• Toxoflavin treatment increased the acetylation of p53 (SIRT1 substrate) and α-tubulin (SIRT2 substrate) in A549 cells.
• Several synthesized toxoflavin derivatives displayed selective SIRT1 inhibition.

Conclusions:

• Toxoflavin is a potent inhibitor of SIRT1 and SIRT2 with demonstrated anticancer activity.
• Toxoflavin's mechanism involves increasing the acetylation of key cellular substrates.
• Toxoflavin and its derivatives represent promising candidates for further development as anticancer agents targeting SIRT1/2.